Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

New induction and postinduction strategies in acute myeloid leukemia

Burnett, Alan Kenneth 2012. New induction and postinduction strategies in acute myeloid leukemia. Current Opinion in Hematology 19 (2) , pp. 76-81. 10.1097/MOH.0b013e3283500a92

Full text not available from this repository.


Purpose of review: Improving or replacing the traditional induction (3 + 7) and consolidation (high-dose cytarabine; Ara-C) as the standard of care for acute myeloid leukemia (AML) has proved disappointing. Recent findings: Recent studies have raised the possibility that daunorubicin dose escalation might have the potential to improve survival. Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemotherapy may yet be a viable option in older patients, and alternative nucleoside analogues in induction could help higher risk subgroups. In consolidation, the number of courses and dose level of Ara-C required are being clarified. New treatments for older patients who will not be subjected to conventional chemotherapy are an active area, but randomized trials have not yet usurped low-dose Ara-C (LDAC). Summary: Recent information in these areas is reviewed.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Lippincott Williams & Wilkins
ISSN: 1065-6251
Last Modified: 25 Jun 2017 03:27

Citation Data

Cited 16 times in Google Scholar. View in Google Scholar

Cited 12 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item